Ranbaxy inks pact with Gilead for low-cost HIV drug
Pharma major Ranbaxy Laboratories Ltd (Ranbaxy) today announced that it has entered into an in-licensing agreement with Gilead Sciences to promote access to high-quality, low-cost generic versions of US firm's HIV medicine emtricitabine in developing countries.
'Ranbaxy and Gilead have a strong collaboration going in the area of HIV/AIDS. We are pleased to extend this association with Gilead that will enable us to offer quality, affordable medicines for the treatment of HIV/AIDS in the developing countries,' Ranbaxy Managing Director Mr Arun Sawhney said in a statement here.
Under the agreement, Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce manufacturing costs, the statement said.
World Health Organisation (WHO) guidelines recommend emtricitabine, as well as tenofovir disoproxil fumarate (TDF), as preferred components of first- and second-line HIV therapy.
However, cost is currently a barrier to broadening access to regimens that include emtricitabine when compared to other regimens including widely used lamivudine-based regimens.
The new agreements will therefore enable Ranbaxy to produce high volumes of FTC/TDF based therapies, thereby establishing sustainable price parity to alternative regimens, the company said.
California-based Gilead sells emtricitabine under the brand name Emtriva.